New research indicates that individuals who come off new GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise plans.
Research printed in a major medical journal points out that while overweight people often shed about a fifth of their body weight while using the jabs, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"People purchasing such medications must be informed of the risk of rapid weight regain when the medication ends," stated expert Dr. Susan Jebb.
Such speed of recovery means a reversion to starting mass within about 18 months.
Comparing Therapies
The analysis, which looked at dozens of trials involving thousands of participants, contrasted the outcomes of these new drugs with other pills.
Researchers point out that people who shed pounds through dieting usually experience a more gradual creep back—around 100 grams monthly—once they finish.
Explaining the Quick Regain
Experts propose the mechanism of the drugs explains the amplified rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating a significant risk."
A Chronic Issue?
Health authorities suggest the jabs for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, due to the significant potential of relapse, the therapy should be considered ongoing.
This opinion is supported by pharmaceutical companies, who say that the results "emphasize the long-term character of excess weight," comparing it to managing conditions like hypertension.
User Accounts
Individuals who have stopped the jabs describe a sudden resurgence of appetite.
"It felt as if a trigger that goes on and you become starving," described a patient.
This difficulty is exacerbated if users have not adopted lasting dietary or behavioural changes during therapy.
Widespread Adoption
Figures suggest that millions of adults in the UK have used weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the highest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians stress that while the jabs are effective tools for weight loss, they are not a standalone solution and lasting health benefits hinges on ongoing lifestyle changes.
